Also Read: Kiran Mazumdar-Shaw compares India to China, questions techies: ‘What use is tech talent without civic sense?’
“I am the sole owner of Biocon, and I need to make sure that I put it in good hands,” Mazumdar-Shaw told Fortune India. “I have seen my niece Claire as my successor, because I think she has proved to me that she can run a company.”
Claire Mazumdar is currently founder and CEO of Bicara Therapeutics, a NASDAQ-listed company incubated by Biocon. She holds degrees from MIT and Stanford, including a PhD in cancer biology, and previously worked with Third Rock Ventures and Rheos Medicines. Bicara was listed in 2024 and has a market capitalisation of over $1.6 billion.
Mazumdar-Shaw also outlined the broader family ecosystem that could support Biocon’s future, including Claire’s brother Eric Mazumdar, a Caltech professor and AI expert, and her husband Thomas Roberts, an oncologist at Massachusetts General Hospital.
As part of a wider organisational overhaul, Biocon has merged its generics and biologics businesses, reduced debt, and simplified its structure. The company is focusing on biosimilars, which account for around 60% of revenue, with 12 products already in the market and about 20 in the pipeline.Also Read: Biocon in very unique position globally as a biosimilars leader: Kiran Mazumdar-Shaw
Leadership transitions are also underway across group companies. Shreehas Tambe has taken over as CEO and managing director of Biocon Biologics, while Siddharth Mittal is set to lead Syngene International from July 1.
Mazumdar-Shaw said the group’s future growth will be anchored in differentiated biosimilars, original biologic drugs, and deeper integration of artificial intelligence across research and development platforms.
